Comprehensive Evaluation of Original Research Sodium-glucose Transporters 2 Inhibitors Based on A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition)
10.3870/j.issn.1004-0781.2025.02.013
- VernacularTitle:基于《中国医疗机构药品评价与遴选快速指南(第二版)》的原研钠-葡萄糖协同转运蛋白2抑制剂综合评价
- Author:
Cheng JI
1
;
Bing ZHOU
;
Pengli ZHU
;
Chao WANG
;
Xunlong ZHONG
;
Aizong SHEN
;
Yi ZHANG
;
Ruolun WANG
;
Weihong GE
;
Zhanjun DONG
;
Zhigang ZHAO
Author Information
1. 南京大学医学院附属鼓楼医院药学部,南京 210008
- Publication Type:Journal Article
- Keywords:
Sodium-dependent glucose transporters 2 inhibitor;
Dagliflozin;
Empagliflozin;
Canagliflozin;
Ertugliflozin;
Henagliflozin;
Overall merit
- From:
Herald of Medicine
2025;44(2):251-258
- CountryChina
- Language:Chinese
-
Abstract:
Objective In order to provide a better reference and basis for the selection of reasonable hypoglycemic drugs for clinical treatment,the study conducted a comprehensive clinical evaluation of the innovator sodium-glucose transporters 2(SGLT-2)inhibitors,based on A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition).Methods The real-world studies,randomized controlled trials,Meta-analysis/systematic review,drug clinical use guidelines,expert consensus and drug description evaluation evidence were collected,and the included drugs were assigned and evaluated from five dimensions:pharmaceutical characteristics,efficacy,safety,economy and other attributes.Results All SGLT-2 inhibitors had evaluation scores above 75,with dagaglifloztin tablets having the highest score of 84.6,and canaglifloztin having the lowest score of 75.1.Conclusions All five original SGLT-2 inhibitors showed good clinical utility,the difference is that the participating original drugs have different advantageous intervals in clinical use.The results show that dagliflozin has the most ideal clinical utility,and its clinical use should be safer and more effective.Due to the short time on the market and insufficient evidence-based reasons,the advantages of clinical use of proline hemegliflozin are not obvious compared with other evaluated drugs.
